Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
Study sponsor: Q32 Bio Inc. · QTTB
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-12Estimated
Enrollment · participants102Estimated
Source updated2024-10-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.